CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities
Net loss	$ (12,335,306)	$ (2,430,111)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	5,668	0
Loss on extinguishment of notes payable	2,403,193	0
Decrease in fair value of derivative liabilities	(667,448)	(536,544)
Amortization of discount on notes payable	298,885	201,719
Amortization of patents and acquired contracts	1,102,423	157,097
Stock-based compensation	2,238,184	1,166,931
Changes in operating assets and liabilities
Accounts receivable	(245,558)	0
Inventories	47,294	0
Prepaid expenses and other current assets	(155,523)	(22,757)
Deposits and other assets	(17,484)	(17,549)
Accounts payable	1,386,113	133,283
Accrued expenses and other current liabilities	549,294	0
Accrued interest on notes payable	73,065	3,667
Net cash used in operating activities	(5,317,200)	(1,344,264)
Cash flows from investing activities
Restricted cash	(3,500,000)	0
Purchases of property and equipment	(52,186)	0
Issuance of short-term note receivable, related party	(3,000,000)	0
Purchases of patents	0	(4,189,255)
Cash and other assets received in acquisition	790,172	0
Net cash used in investing activities	(5,762,014)	(4,189,255)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	6,487,850	3,548,343
Proceeds from issuance of convertible notes payable, net of issuance costs	2,905,128	4,950,000
Proceeds from issuance of notes payable	500,000	0
Payments on short-term notes payable, related party	(100,000)	0
Net cash provided by financing activities	9,792,978	10,046,869
Net increase in cash and cash equivalents	(1,286,236)	4,513,350
Cash and cash equivalents, beginning of period	1,518,684	0
Cash and cash equivalents, end of period	232,448	4,513,350
Supplemental disclosures of cash flow information
Cash paid for interest	159,822	0
Cash paid for income taxes	0	0
Supplemental disclosures of non-cash investing and financing activities
Convert outstanding LLC accrued liabilities to member contribution, January 2013	0	12,783
Allocation of fair value from Series A-2 redeemable convertible preferred stock to Series A-1 redeemable convertible preferred stock (See Note 7)	0	865,985
Allocation of fair value from notes payable to Series A-1 redeemable convertible preferred stock (See Note 6)	0	2,392,889
Fair value of notes payable redemption derivative liability	0	582,903
Fair value of Series A-1 redeemable convertible preferred stock anti-dilution derivative liability	0	548,465
Accrued guaranteed payments and deferred expenses associated with purchased patent assets	3,951,870	0
Offset of short-term related party notes payable and receivable	3,000,000	3,000,000
Fair value of convertible notes payable redemption derivative liability	316,200	518,013
Fair value of common stock warrants	145,958	0
Acquisition of patents	2,653,533	0
Transfer of Series A redeemable convertible preferred stock to preferred stock	3,392,950	0
Series A-1 Redeemable Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from issuance of redeemable convertible preferred stock	0	50,000
Series A-2 Redeemable Convertible Preferred Stock [Member]
Cash flows from financing activities
Proceeds from issuance of redeemable convertible preferred stock	$ 0	$ 1,498,526